Enhanced drug metabolism in young children with cystic fibrosis
- PMID: 9370904
- PMCID: PMC1717318
- DOI: 10.1136/adc.77.3.239
Enhanced drug metabolism in young children with cystic fibrosis
Abstract
The effect of cystic fibrosis on caffeine metabolism was studied in young children using the caffeine breath test. Eight children with cystic fibrosis aged 2-6 years and nine age matched controls were studied on a single occasion, and the cumulative percentage of labelled caffeine exhaled as carbon dioxide measured over two hours. This was significantly higher in the patients with cystic fibrosis than in controls, suggesting an increase in the CYP1A2 metabolic pathway in the former. The fact that these were young children with minimal lung and liver disease suggests that enhanced drug metabolism in children with cystic fibrosis is hereditary rather than secondary to lung and liver damage.
Similar articles
-
Inhibition of caffeine metabolism by ciprofloxacin in children with cystic fibrosis as measured by the caffeine breath test.Br J Clin Pharmacol. 1994 Dec;38(6):573-6. doi: 10.1111/j.1365-2125.1994.tb04399.x. Br J Clin Pharmacol. 1994. PMID: 7888295 Free PMC article. Clinical Trial.
-
Caffeine metabolism in cystic fibrosis: enhanced xanthine oxidase activity.Clin Pharmacol Ther. 1994 Nov;56(5):521-9. doi: 10.1038/clpt.1994.173. Clin Pharmacol Ther. 1994. PMID: 7955816
-
Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test.Br J Clin Pharmacol. 1998 Feb;45(2):176-8. doi: 10.1046/j.1365-2125.1998.00684.x. Br J Clin Pharmacol. 1998. PMID: 9491835 Free PMC article.
-
Biomarkers in Paediatric Cystic Fibrosis Lung Disease.Paediatr Respir Rev. 2015 Sep;16(4):213-8. doi: 10.1016/j.prrv.2015.05.004. Epub 2015 May 12. Paediatr Respir Rev. 2015. PMID: 26051089 Review.
-
Liver Disease in the young adult with cystic fibrosis.Clin Liver Dis (Hoboken). 2014 Oct 24;4(4):84-85. doi: 10.1002/cld.414. eCollection 2014 Oct. Clin Liver Dis (Hoboken). 2014. PMID: 30992928 Free PMC article. Review. No abstract available.
Cited by
-
Potential of anti-inflammatory treatment for cystic fibrosis lung disease.J Inflamm Res. 2010;3:61-74. doi: 10.2147/jir.s8875. Epub 2010 Aug 10. J Inflamm Res. 2010. PMID: 22096358 Free PMC article.
-
A systematic review of pharmacokinetics studies in children with protein-energy malnutrition.Eur J Clin Pharmacol. 2010 Oct;66(10):1025-35. doi: 10.1007/s00228-010-0851-0. Epub 2010 Jun 16. Eur J Clin Pharmacol. 2010. PMID: 20552179
-
Reduced NHE3-mediated Na+ absorption increases survival and decreases the incidence of intestinal obstructions in cystic fibrosis mice.Am J Physiol Gastrointest Liver Physiol. 2009 Apr;296(4):G886-98. doi: 10.1152/ajpgi.90520.2008. Epub 2009 Jan 22. Am J Physiol Gastrointest Liver Physiol. 2009. PMID: 19164484 Free PMC article.
-
Drug disposition in cystic fibrosis.Clin Pharmacokinet. 1998 Oct;35(4):313-29. doi: 10.2165/00003088-199835040-00004. Clin Pharmacokinet. 1998. PMID: 9812180 Review.
-
Drug metabolism of ciprofloxacin, ivacaftor, and raloxifene by Pseudomonas aeruginosa cytochrome P450 CYP107S1.J Biol Chem. 2024 Aug;300(8):107594. doi: 10.1016/j.jbc.2024.107594. Epub 2024 Jul 18. J Biol Chem. 2024. PMID: 39032655 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical